| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/05/2011 | CA2778680A1 N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| 05/05/2011 | CA2778265A1 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition |
| 05/05/2011 | CA2778219A1 Positive allosteric modulators (pam) |
| 05/05/2011 | CA2778181A1 Novel enteric combination therapy |
| 05/05/2011 | CA2778171A1 Bridged artificial nucleoside and nucleotide |
| 05/05/2011 | CA2778151A1 Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures |
| 05/05/2011 | CA2778142A1 Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms |
| 05/05/2011 | CA2777937A1 Solid pharmaceutical compositions containing an integrase inhibitor |
| 05/05/2011 | CA2777896A1 Androgen receptor modulating compounds |
| 05/05/2011 | CA2777857A1 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| 05/05/2011 | CA2777827A1 Alleviating oxidative stress disorders with pufa derivatives |
| 05/05/2011 | CA2777671A1 (1,1, 1,3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis |
| 05/05/2011 | CA2777632A1 Imidazole derivatives as casein kinase inhibitors |
| 05/05/2011 | CA2777539A1 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors |
| 05/05/2011 | CA2777532A1 Stable rasagiline composition |
| 05/05/2011 | CA2777152A1 Substituted 3-phenylpropionic acids and the use thereof |
| 05/05/2011 | CA2777128A1 Methods and compositions for treating cancer |
| 05/05/2011 | CA2777033A1 Spirolactam derivatives and uses of same |
| 05/05/2011 | CA2776994A1 Chromenone derivatives with anti-tumour activity |
| 05/05/2011 | CA2776319A1 Ite for cancer intervention and eradication |
| 05/05/2011 | CA2775413A1 Compounds for the treatment of dyslipidemia and related diseases |
| 05/05/2011 | CA2774704A1 Ophthalmic formulation and method of manufacture thereof |
| 05/05/2011 | CA2742393A1 Dosing regimen associated with long-acting injectable paliperidone esters |
| 05/04/2011 | EP2316976A1 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 05/04/2011 | EP2316968A1 Antisense modulation of apolipoprotein (A) expression |
| 05/04/2011 | EP2316953A2 Identification of novel E2F target genes and use thereof |
| 05/04/2011 | EP2316943A1 DSRNA for treating viral infection |
| 05/04/2011 | EP2316942A1 Conserved HBV and HCV sequences useful for gene silencing |
| 05/04/2011 | EP2316941A2 Compositions and their uses directed to IL-4R alpha |
| 05/04/2011 | EP2316937A1 Dna encoding polypeptide involved in biosynthesis of herboxidiene |
| 05/04/2011 | EP2316935A1 Aptamer against il-17 and use thereof |
| 05/04/2011 | EP2316845A1 Specific binding agents of human angiopoietin-2 |
| 05/04/2011 | EP2316843A1 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 05/04/2011 | EP2316839A1 Antiviral compounds |
| 05/04/2011 | EP2316837A1 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| 05/04/2011 | EP2316836A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors |
| 05/04/2011 | EP2316835A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 05/04/2011 | EP2316834A1 Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase |
| 05/04/2011 | EP2316833A1 Process for the preparation of Cyclopamine analogue compounds |
| 05/04/2011 | EP2316832A1 Cyclopamine analogues and methods of use thereof |
| 05/04/2011 | EP2316831A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| 05/04/2011 | EP2316830A2 N-sulphonylated amino acid derivatives and their use as matriptase inhibitors |
| 05/04/2011 | EP2316829A1 Heterocyclic derivatives as modulators of ion channels |
| 05/04/2011 | EP2316828A1 Piperazine derivatives and their use as therapeutic agents |
| 05/04/2011 | EP2316827A1 Piperazine derivatives and their use as therapeutic agents |
| 05/04/2011 | EP2316826A1 Pyridazine derivatives and their use as therapeutics agents |
| 05/04/2011 | EP2316825A1 Pyridyl derivatives and their use as therapeutic agents |
| 05/04/2011 | EP2316820A1 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| 05/04/2011 | EP2316531A1 Augmented cognitive training |
| 05/04/2011 | EP2316530A1 Triglycerides, fatty acids, alcohols as CNS modulators |
| 05/04/2011 | EP2316491A1 Cell proliferation inhibitor |
| 05/04/2011 | EP2316488A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 05/04/2011 | EP2316476A2 Antigenic peptides derived from telomerase |
| 05/04/2011 | EP2316472A1 Composition for transmucosal delivery of polypeptides |
| 05/04/2011 | EP2316470A2 Peptidomimetic inhibitors of post-proline cleaving enzymes |
| 05/04/2011 | EP2316469A1 Delivery system and methods for protecting and administering dextroamphetamine |
| 05/04/2011 | EP2316468A1 Delivery system and methods for protecting and administering dextroamphetamine |
| 05/04/2011 | EP2316467A1 Use of a prolactin variant for treating cancer |
| 05/04/2011 | EP2316461A1 Composition for treating dermal tissue |
| 05/04/2011 | EP2316460A1 Solution for peritoneal dialysis |
| 05/04/2011 | EP2316459A1 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| 05/04/2011 | EP2316458A1 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| 05/04/2011 | EP2316457A1 Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
| 05/04/2011 | EP2316456A1 Compositions for affecting weight loss comprising naltrexone and bupropion |
| 05/04/2011 | EP2316455A1 Pharmaceutical compositions for treating cancer |
| 05/04/2011 | EP2316454A1 Dosage form containing pantoprazole as active ingredient |
| 05/04/2011 | EP2316453A1 Methods of reducing adverse events associated with pirfenidone therapy |
| 05/04/2011 | EP2316452A1 Pyrrol derivatives, uses thereof |
| 05/04/2011 | EP2316451A1 Use of melatonin in preventing postoperative complications |
| 05/04/2011 | EP2316450A1 Amino-methyl substituted tetracycline compounds |
| 05/04/2011 | EP2316449A1 Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| 05/04/2011 | EP2316448A1 An entacapone-containing oral dosage form |
| 05/04/2011 | EP2316447A1 Method of inhibiting remnant lipoprotein production |
| 05/04/2011 | EP2316446A1 Counteracting drug-induced obesity using GLP-1 agonists |
| 05/04/2011 | EP2316445A1 HUMAN beta3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME |
| 05/04/2011 | EP2316444A2 Use of alkanedicaroxylic acids and retinoids for the treatment of rosacea and other inflammatory skin diseases |
| 05/04/2011 | EP2316443A1 Medicinal formulation for treating nail ailments |
| 05/04/2011 | EP2316442A1 Rapid dissolution formulation of a calcium receptor-active compound |
| 05/04/2011 | EP2316441A1 Bisphosphonates for treating endometriosis |
| 05/04/2011 | EP2316440A1 Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent |
| 05/04/2011 | EP2316438A1 Tape , in particular adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent |
| 05/04/2011 | EP2316437A1 Multilayer drug delivery system with barrier against reservoir material flow |
| 05/04/2011 | EP2316435A1 Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine |
| 05/04/2011 | EP2316434A1 Orally disintegrating tablets of memantine |
| 05/04/2011 | EP2316433A1 Orally disintegrating tablets of flurbiprofen |
| 05/04/2011 | EP2316432A1 Compound containing fesoterodine and roughage |
| 05/04/2011 | EP2316431A1 Solid oral composition comprising a S1P receptor agonist and a sugar alcohol |
| 05/04/2011 | EP2316429A1 Matrix for sustained, invariant and independent release of active compounds |
| 05/04/2011 | EP2316428A1 Matrix for sustained, invariant and independent release of active compounds |
| 05/04/2011 | EP2316427A1 Compositions and methods for improved delivery of hydrophobic therapeutic agents |
| 05/04/2011 | EP2316426A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 05/04/2011 | EP2316425A1 Liquid formulations comprising an active agent, glycerine and sorbitol |
| 05/04/2011 | EP2316424A1 Pharmaceutical preparations and methods for their regional administration |
| 05/04/2011 | EP2316422A1 Liquid compositions comprising valsartan |
| 05/04/2011 | EP2316421A1 Bupivacaine-containing injectable depot composition |
| 05/04/2011 | EP2316420A1 Method to reduce pain |
| 05/04/2011 | EP2316377A1 Drug-Delivery Endovascular Stent And Method For Treating Restenosis |
| 05/04/2011 | EP2315832A1 Micro-rna mediated modulation of colony stimulating factors |
| 05/04/2011 | EP2315768A1 Thieno-pyridine derivatives as mek inhibitors |
| 05/04/2011 | EP2315767A2 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof |